Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Issues Earnings Results, Beats Estimates By $0.05 EPS

Key Points

• Kiniksa Pharmaceuticals reported a quarterly EPS of $0.23, significantly surpassing analysts' expectations of $0.08.
• Insider trading showed notable activity, with Ross Moat and Barry D. Quart selling substantial amounts of shares, indicating a 74.56% and 49.58% decrease in their holdings, respectively.
• Several analysts have increased their price targets for Kiniksa's shares, with Jefferies Financial Group setting a new objective at $45.00, reflecting strong confidence in the company's performance.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported $0.23 EPS for the quarter, beating the consensus estimate of $0.18 by $0.05, Zacks reports. The firm had revenue of $156.80 million during the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. Kiniksa Pharmaceuticals International updated its FY 2025 guidance to EPS.

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ:KNSA traded up $1.72 on Friday, hitting $31.98. The company's stock had a trading volume of 1,072,119 shares, compared to its average volume of 611,693. Kiniksa Pharmaceuticals International has a 12 month low of $17.82 and a 12 month high of $32.15. The company has a market capitalization of $2.33 billion, a price-to-earnings ratio of 799.70 and a beta of 0.14. The stock's 50-day moving average is $28.38 and its two-hundred day moving average is $24.07.

Insiders Place Their Bets

In related news, COO Eben Tessari sold 45,042 shares of the company's stock in a transaction dated Wednesday, June 11th. The stock was sold at an average price of $30.51, for a total value of $1,374,231.42. Following the completion of the sale, the chief operating officer owned 72,363 shares in the company, valued at approximately $2,207,795.13. This represents a 38.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Mark Ragosa sold 18,299 shares of the stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $28.80, for a total value of $527,011.20. Following the transaction, the chief financial officer directly owned 27,009 shares of the company's stock, valued at $777,859.20. This trade represents a 40.39% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 320,981 shares of company stock worth $9,189,467 over the last three months. Company insiders own 53.48% of the company's stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of large investors have recently modified their holdings of the business. Millennium Management LLC lifted its stake in shares of Kiniksa Pharmaceuticals International by 8.7% in the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company's stock valued at $18,815,000 after purchasing an additional 67,452 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Kiniksa Pharmaceuticals International by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,843 shares of the company's stock worth $507,000 after purchasing an additional 1,002 shares in the last quarter. Finally, Amundi bought a new position in shares of Kiniksa Pharmaceuticals International in the first quarter valued at approximately $348,000. Institutional investors and hedge funds own 53.95% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on KNSA. Wedbush reaffirmed an "outperform" rating and set a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Wells Fargo & Company upped their price objective on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a report on Wednesday, July 9th. Jefferies Financial Group increased their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research report on Tuesday. Finally, Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research note on Saturday. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Kiniksa Pharmaceuticals International has an average rating of "Buy" and a consensus price target of $41.17.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.